Global Biosimulation Market

Global Biosimulation Market Size, Share, Growth Analysis, By Application(drug development, drug discovery), By End user(pharmaceutical and biotechnology companies, academic institutes and research laboratories) - Industry Forecast 2024-2031


Report ID: SQMIG35I2104 | Region: Global | Published Date: April, 2024
Pages: 219 | Tables: 64 | Figures: 75

Global Biosimulation Market Regional Insights

In 2021, North America had a revenue share of more than 45.0%. This expansion is attributed to the presence of key players, increased healthcare digitization, and the rising prevalence of chronic health issues. Furthermore, the use of in-silico models during regulatory policy enforcement to ensure high patient safety and treatment standards is contributing to regional market growth. Geographically, North America will dominate the worldwide biosimulation technology market in the years to come as a result of technical improvements, market expansion for biologics and biosimilars, high healthcare spending, and the presence of numerous pharma and biotech firms. Additionally, the U.S. Food and Drug Administration (FDA) highly suggests using simulation methods in drug research and development, hence promoting the expansion of the North American biosimulation technology market. In the global market for biosimulation technology, Europe is the region with the quickest growth. High healthcare costs and an increase in R&D activities are the main causes of the fastest growth in the region.

In the upcoming years, Asia Pacific is anticipated to see the fastest market growth. The region is predicted to experience a rapid increase in investment in the growth of the pharmaceutical and healthcare sectors. The Asia Pacific region's biosimulation market is increasing significantly due to the presence of numerous top contract research firms there as well as the expanding FDIs from leading pharmaceutical MNCs. The development of the pharmaceutical and healthcare sectors in this region is being aided by the availability of inexpensive production inputs and favourable government policies, which is anticipated to boost the expansion of the Asia Pacific biosimulation market.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Biosimulation Market size was valued at USD 2.81 billion in 2022 and is poised to grow from USD 3.28 billion in 2023 to USD 11.46 billion by 2031, growing at a CAGR of 16.90% during the forecast period (2024-2031).

To gain a larger market share, key players used competitive sustainability strategies such as product development and geographical presence expansion. Market leaders are also more likely to address unmet needs and provide economic value through consistent product upgrades. 'Certara', 'Dassault Systèmes SE', 'Simulations Plus Inc.', 'Schrödinger Inc.', 'Physiomics Plc', 'Advanced Chemistry Development Inc.', 'In silico biosciences Inc.', 'Genedata AG', 'Evidera Inc.', 'Leadscope Inc.', 'Insilico Biotechnology AG', 'Rhenovia Pharma SAS', 'Entelos Inc.', 'Biocomputing Platforms Ltd.', 'Rosa & Co. LLC', 'Genedata AG', 'OpenEye Scientific Software Inc.', 'Nexelis', 'Compugen Ltd.', 'Chemical Computing Group ULC'

The increasing pressure to lower healthcare costs, rising demand for biosimilars due to their cost-effectiveness, rising prevalence of various diseases, rising number of off-patent drugs, positive results in ongoing clinical trials, and rising demand for biosimilars in various therapeutic applications such as rheumatoid arthritis and blood disorders are some of the main factors driving growth in the global biosimilars market.

One of the key trends driving market growth is the rising incidence of drug relapse cases due to drug resistance in diseases such as cancer, tuberculosis, and other bacterial infections.

In 2021, North America had a revenue share of more than 45.0%. This expansion is attributed to the presence of key players, increased healthcare digitization, and the rising prevalence of chronic health issues. Furthermore, the use of in-silico models during regulatory policy enforcement to ensure high patient safety and treatment standards is contributing to regional market growth. Geographically, North America will dominate the worldwide biosimulation technology market in the years to come as a result of technical improvements, market expansion for biologics and biosimilars, high healthcare spending, and the presence of numerous pharma and biotech firms. Additionally, the U.S. Food and Drug Administration (FDA) highly suggests using simulation methods in drug research and development, hence promoting the expansion of the North American biosimulation technology market. In the global market for biosimulation technology, Europe is the region with the quickest growth. High healthcare costs and an increase in R&D activities are the main causes of the fastest growth in the region.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Biosimulation Market

Product ID: SQMIG35I2104

$5,300
BUY NOW GET FREE SAMPLE